Yin Li, Rui Xu, Yuanteng Zhang, Kai Jiang, Tiecheng Zhong
{"title":"TRPV4-dependent signaling pathways play essential regulatory roles in high salt-induced cardiac hypertrophy via autophagic alterations.","authors":"Yin Li, Rui Xu, Yuanteng Zhang, Kai Jiang, Tiecheng Zhong","doi":"10.1097/FJC.0000000000001711","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiac hypertrophy, initially referred to as an adaptive response, would gradually transit to decompensated states over time, contributing to hypertension, and ultimately heart failure under salt overload. The cellular and molecular mechanisms driving salt-induced cardiac hypertrophy, as well as the signaling pathways responsible for this shift from compensation to decompensation, still remain insufficiently understood. Transient receptor potential vanilloid 4 (TRPV4) is ubiquitously expressed in cardiomyocytes, participating in cardiac remodeling and dysfunction. This study investigated TRPV4-relevant mechanisms in salt-induced cardiac hypertrophy. Knockdown of TRPV4 with cardiac gene transfer of Lv-shTRPV4 attenuated salt-induced cardiac hypertrophy, ROS generation, perivascular fibrosis and Akt & mTOR phosphorylation in adult rats. The in vitro results suggest that exposing cardiomyocytes to high-salt induced a concentration-dependent increase in autophagy, which was initially a rising phase and later followed by a declining phase. Salt-induced autophagic activity was enhanced by inhibiting Class I PI3-Kinase (PI3KC1) with LY294002 or Akt with AZD5363, but got undermined by AMPK inhibition with Compound C (CC) or SIRT1 inhibition with EX-527. Additionally, blockade of PI3KC1/Akt pathway significantly attenuated high salt-induced ROS generation and cardiac hypertrophy, whilst blockade of AMPK/SIRT1 pathway exacerbated high salt-induced cardiac hypertrophy via ROS accumulation. Thus, both PI3KC1 and AMPK signaling pathways participate in salt-induced cardiac hypertrophy via shared upstream component of TRPV4: lower salt triggers AMPK, scavenges ROS, preventing cardiac hypertrophy, whilst higher salt activates PI3KC1 with opposite effects. Our findings illuminate potential therapeutic effects of interfering TRP-related channels on high salt-induced hypertrophy and other mechanical stretch force-associated diseases.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001711","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Cardiac hypertrophy, initially referred to as an adaptive response, would gradually transit to decompensated states over time, contributing to hypertension, and ultimately heart failure under salt overload. The cellular and molecular mechanisms driving salt-induced cardiac hypertrophy, as well as the signaling pathways responsible for this shift from compensation to decompensation, still remain insufficiently understood. Transient receptor potential vanilloid 4 (TRPV4) is ubiquitously expressed in cardiomyocytes, participating in cardiac remodeling and dysfunction. This study investigated TRPV4-relevant mechanisms in salt-induced cardiac hypertrophy. Knockdown of TRPV4 with cardiac gene transfer of Lv-shTRPV4 attenuated salt-induced cardiac hypertrophy, ROS generation, perivascular fibrosis and Akt & mTOR phosphorylation in adult rats. The in vitro results suggest that exposing cardiomyocytes to high-salt induced a concentration-dependent increase in autophagy, which was initially a rising phase and later followed by a declining phase. Salt-induced autophagic activity was enhanced by inhibiting Class I PI3-Kinase (PI3KC1) with LY294002 or Akt with AZD5363, but got undermined by AMPK inhibition with Compound C (CC) or SIRT1 inhibition with EX-527. Additionally, blockade of PI3KC1/Akt pathway significantly attenuated high salt-induced ROS generation and cardiac hypertrophy, whilst blockade of AMPK/SIRT1 pathway exacerbated high salt-induced cardiac hypertrophy via ROS accumulation. Thus, both PI3KC1 and AMPK signaling pathways participate in salt-induced cardiac hypertrophy via shared upstream component of TRPV4: lower salt triggers AMPK, scavenges ROS, preventing cardiac hypertrophy, whilst higher salt activates PI3KC1 with opposite effects. Our findings illuminate potential therapeutic effects of interfering TRP-related channels on high salt-induced hypertrophy and other mechanical stretch force-associated diseases.
期刊介绍:
Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias.
Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.